Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Crown Holdings: Durable FCF Beat and Improving Cash Flow Make a Buy Case
Strong quarterly free cash flow and steady operations create an asymmetric risk-reward for a 6-12 month position
Crown Holdings (CCK) is generating meaningful free cash flow after a volatile cycle. Operating cash jumped to $580m in Q3 2025 with modest investing (...
Workday: Market Panic Equals Opportunity - 5 Reasons to Buy WDAY Now
Fundamentals intact, valuation reset, and a clear risk/reward for a tactical swing trade
Shares of Workday (WDAY) have been punished recently, creating a rare entry point on a company with recurring revenue, improving margins, strong free ...
Veeva Rebound Trade: Buy the Post-Decline Setup Around $180 — Targets $230/$280
High-margin life-sciences software with steady revenue rebound and buyback tailwinds — tactical long swing with defined risk limits.
Veeva (VEEV) is offering a tactical long entry after a meaningful pullback. The business shows accelerating revenue and healthy margins, operating cas...
Buy Merck on a Controlled Pullback — 2026 Trade with a Time-Limited Thesis
Strong cash flow and a healthy dividend make MRK a tactical buy for 2026, but guidance misses and concentrated oncology exposure keep a clock ticking.
Merck looks like a pragmatic long for 2026: the company is generating ample cash, delivered roughly $8.13 of FY2025 EPS (sum of quarterly EPS), and tr...
Selective Insurance: A Durable Regional Franchise with Room to Re-rate in 2026
Actionable long - entry, stop, targets and a case built on underwriting discipline, cash flow and a modest yield
Selective Insurance (SIGI) looks like a quietly profitable regional P&C business trading at a reasonable multiple to book and generating strong operat...
Bar Harbor Bankshares: Upgrade to Long - A Modest Bounce Plays to Quality and Yield
Regional bank with stable earnings, improving interest income and a healthy book - a tactical long with defined stops and upside targets.
I’m upgrading BHB to a buy for a tactical swing. The stock looks worth owning near $35.60: Bar Harbor reported healthy net interest income growth, a...
Arm: Monetizing the CPU Orchestration Layer as Agentic AI Spreads
A tactical long with defined entries and stops—play the royalty leverage as compute becomes heterogeneous and orchestrated.
Arm sits at the intersection of mobile dominance and a rising need for power-efficient orchestration in heterogeneous AI stacks. With a business that ...
Kroger: Defensive Income Compounder — Buy the Dip for a Volatile Market
Use Kroger's scale, private-label margins and steady cash flow to anchor a long trade while markets remain choppy.
Kroger (KR) is a defensive, cash-generative grocery operator that recently suffered a headline quarterly loss but still generates reliable operating c...
Dollar Tree: Still a Value Call After the Rally — Buy the 120–126 Zone
Strong cash generation, margin recovery and a proven multi-price play make DLTR a tactical long while the market overly fixates on short-term noise.
Dollar Tree (DLTR) has delivered consistent top-line growth and improved profitability through its multi-price strategy and private-label mix. Recent ...
Buy Equinix Now: The Data‑Center King with Durable Cash Flow and Reasonable Entry
Scale, sticky customers, and rising AI spend make EQIX a pragmatic long with defined risk controls.
Equinix runs 260 global data centers and delivers steady revenue, rising operating margins and strong operating cash flow. Recent quarterly results sh...
Pacira (PCRX) - Sell-off Prices In Generic Fear Today, Not Reality for Years
Strong cash flow, high gross margins and manageable leverage make PCRX a tactical long: generic competition is real but likely delayed — the market is over-discounting the runway.
Pacira BioSciences is being punished for a now-public ANDA filing against EXPAREL and headline litigation. The company’s Q3 2025 results show health...
Biogen FY25: EPS Holding Up as MS Sales Slide — Tactical Long on Pullback
Earnings show stable profitability but the legacy multiple sclerosis franchise is the main growth headache; trade a disciplined, catalyst-driven long.
Biogen reported roughly stable EPS through FY25 despite ongoing pressure in its multiple sclerosis (MS) franchise, which accounted for 45% of revenue ...